In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

SpeeDx announces Series A round

Executive Summary

SpeeDx Pty. Ltd. raised an undisclosed sum in its Series A financing to new backer Northpond Ventures, which adds a board member. The company’s ResistancePlus MG can diagnose Mycoplasma genitalium and genetic markers linked to macrolide antibiotic resistance. The diagnostic is currently in the clinic and an FDA filing is expected later this year. The test will soon be available in Europe on the Cepheid GeneXpert system. SpeeDx also has a ResistancePlus test for detecting gonorrhea infection and markers linked to susceptibility to ciprofloxacin.

Deal Industry
  • In Vitro Diagnostics
  • Research, Analytical Equipment & Supplies
    • PCR & Amplification Tools
  • Medical Devices
    • Diagnostic Equipment & Supplies
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies